Cellectar Biosciences, Inc. Resources
Patients
News & Media
Investors
Contact
Cellectar Biosciences, Inc.
Home
About
Overview
Partnerships
Management Team
Board of Directors
Platform
Overview
Posters & Publications
Product Pipeline
Overview
Iopofosine
Clinical Studies
Overview
Waldenstrom’s Macroglobulinemia Phase 2 Study
Active, not recruiting
Relapsed or Refractory Select B-Cell Malignancies Clinical Study
Active, not recruiting
Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG
Active, not recruiting
Patients
News & Media
Investors
Contact
Presentations
Investors
Investors
Overview
News / Events
Overview
Press Releases
IR Calendar
Email Alerts
Company Info
Overview
Profile
Presentations
Management Team
Contacts
FAQ
Financial Info
Overview
Balance Sheet
Income Statement
Cash Flow
Financial Results
Stock Data
Overview
Quote
Charts
Historical Data
SEC Filings
Overview
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Governance
Overview
Board of Directors
Board Committees
Governance Documents
Investor Tools
Email Alerts
Contacts
RSS News Feed
Company Information
Overview
Profile
Presentations
Management Team
Contacts
FAQ
Corporate Presentation - May 2025
